Free Trial
→ A free stock pick, from me to you (From Behind the Markets) (Ad)tc pixel
NASDAQ:CNTX

Context Therapeutics Q3 2026 Earnings Date & Estimates

Context Therapeutics logo
$0.19 -0.01 (-6.14%)
As of 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Context Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Context Therapeutics in Q3 2026

Context Therapeutics is expected to post earnings of -$0.09 per share. In the same quarter a year earlier Context Therapeutics reported -$0.10 per share. Context Therapeutics last reported on August 5, 2026, posting -$0.15 per share and missing the -$0.0921 consensus estimate. Context Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.09
Prior-Year EPS
-$0.10

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.15 (Missed by -$0.0579)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Context Therapeutics Q3 2026 Earnings FAQ

Context Therapeutics (NASDAQ:CNTX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Context Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 19, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Context Therapeutics to post earnings of -$0.09 per share for Q3 2026.

Context Therapeutics Earnings Headlines

CNTX Updates CT-95 Cancer Study as Trial Is Listed as Terminated
November 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cntx-updates-ct-95-cancer-study-as-trial-is-listed-as-terminated?utm_source=marketbeat.com&utm_medium=referral
Context Therapeutics (CNTX) Expected to Announce Earnings on Wednesday
November 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31175572
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Context Therapeutics (CNTX) Stock Forecast & Price Target
November 3, 2026  |  tipranks.comhttps://www.tipranks.com/stocks/cntx/forecast
Context Doses First Patient In Phase 1 For Cancer Drug CT-202
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689673/context-doses-first-patient-in-phase-1-for-cancer-drug-ct-202.aspx
Context Doses First Patient In Phase 1 For Cancer Drug CT-202
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689673/context-doses-first-patient-in-phase-1-for-cancer-drug-ct-202.aspx
See More Context Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email.

About Context Therapeutics

Context Therapeutics (NASDAQ:CNTX) (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens.

Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers. The company also maintains earlier-stage programs involving additional cancer targets.

Historically, Context Therapeutics focused on therapies for hormone-driven cancers, including development of selective progesterone receptor modulators, before shifting its primary emphasis toward T-cell-engaging antibody therapies. The company is based in Philadelphia, Pennsylvania, and its programs are being advanced through clinical and preclinical development for potential use in oncology markets.

View Context Therapeutics Profile
Earnings Tools